Clinical Trials Browser

Phase 2 × Neoplasm, Residual × Breast × Clear all

NCT03384914 2026-03-06

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms, Neoplasm, Residual, Breast Neoplasms, Male

NCT05708235 2026-03-05

MiRaDoR

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

NCT07069595 2026-03-05

PREDICT-RD

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04434040 2025-08-19

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04768426 2025-03-20

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04841148 2025-03-11

PALAVY

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

NCT01401959 2018-06-15

Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

Phase 2 Completed

127 enrolled 11 charts

Breast Neoplasms, Neoplasm, Residual